Transcriptomics Comprehensive Study by Type (Microarray, Real-time PCR, Sequencing Technology (Sanger Sequencing, RNA-Sequencing)), Application (Diagnostics & Disease Profiling, Drug Discovery, Others), Product & Services (Consumables, Instruments, Software, Services), End User (Government Institutes & Academic Centers, Pharmaceutical & Biotechnology Companies, Contract research Organizations (CROs)) Players and Region - Global Market Outlook to 2026

Transcriptomics Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 13.2%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Huge government spending in healthcare segment will help to boost global transcriptomics market in the forecasted period. Transcriptomics is the study of entire set of RNA transcripts produced by the genome of any organism. Upsurge in advancements in the field of transcriptomics including extensive use of RNA-sequencing. New innovations such as those pertaining to next-generation sequencing (NGS) and RNA interference (RNAi) have birthed as a result of the technological advancements in the international transcriptomics market. With enhanced precision and accuracy, these cutting-edge technologies can be put to use with a view to help researcher’s investigator the transcriptional activity of a vast range of diverse organisms.
According to AMA, the market for Transcriptomics is expected to register a CAGR of 13.2% during the forecast period to 2026. This growth is primarily driven by Increase in Advancements in the Field Of Transcriptomics Such As Extensive Use of RNA-Sequencing and Increase in Application of Transcriptomics, Which Includes Drug Discovery.

Globally, a noticeable market trend is evident Upsurge in Funding and Grants By Various Private and Government Organizations . The Health Care Technology sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as QIAGEN (Exiqon) (Germany), Thermo Fisher Scientific Inc. (United States), Illumina, Inc. (United States), Agilent Technologies (United States), GE Healthcare Dharmacon Inc. (United States), Bio-Rad Laboratories, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (United States), Fluidigm Corporation (United States) and Promega Corporation. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Increase in Advancements in the Field Of Transcriptomics Such As Extensive Use of RNA-Sequencing
  • Increase in Application of Transcriptomics, Which Includes Drug Discovery

Market Trend
  • Upsurge in Funding and Grants By Various Private and Government Organizations
  • Growing Amount of Investments Directed Toward Research and Development Activities In Molecular Genetics

Restraints
  • High Cost of Service
  • Certain Drawbacks of RNA Sequencing

Opportunities
Increasing Government Spending In Emerging Countries
Challenges
Dearth of Trained Professionals

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Transcriptomics Study Sheds Light on
— The Transcriptomics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Transcriptomics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Transcriptomics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Microarray
  • Real-time PCR
  • Sequencing Technology [Sanger Sequencing, RNA-Sequencing]
By Application
  • Diagnostics & Disease Profiling
  • Drug Discovery
  • Others
By Product & Services
  • Consumables
  • Instruments
  • Software
  • Services

By End User
  • Government Institutes & Academic Centers
  • Pharmaceutical & Biotechnology Companies
  • Contract research Organizations (CROs)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Advancements in the Field Of Transcriptomics Such As Extensive Use of RNA-Sequencing
      • 3.2.2. Increase in Application of Transcriptomics, Which Includes Drug Discovery
    • 3.3. Market Challenges
      • 3.3.1. Dearth of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Upsurge in Funding and Grants By Various Private and Government Organizations
      • 3.4.2. Growing Amount of Investments Directed Toward Research and Development Activities In Molecular Genetics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transcriptomics, by Type, Application, Product & Services, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Transcriptomics (Value)
      • 5.2.1. Global Transcriptomics by: Type (Value)
        • 5.2.1.1. Microarray
        • 5.2.1.2. Real-time PCR
        • 5.2.1.3. Sequencing Technology [Sanger Sequencing, RNA-Sequencing]
      • 5.2.2. Global Transcriptomics by: Application (Value)
        • 5.2.2.1. Diagnostics & Disease Profiling
        • 5.2.2.2. Drug Discovery
        • 5.2.2.3. Others
      • 5.2.3. Global Transcriptomics by: Product & Services (Value)
        • 5.2.3.1. Consumables
        • 5.2.3.2. Instruments
        • 5.2.3.3. Software
        • 5.2.3.4. Services
      • 5.2.4. Global Transcriptomics by: End User (Value)
        • 5.2.4.1. Government Institutes & Academic Centers
        • 5.2.4.2. Pharmaceutical & Biotechnology Companies
        • 5.2.4.3. Contract research Organizations (CROs)
      • 5.2.5. Global Transcriptomics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Transcriptomics (Price)
      • 5.3.1. Global Transcriptomics by: Type (Price)
  • 6. Transcriptomics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. QIAGEN (Exiqon) (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Illumina, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare Dharmacon Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co., Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fluidigm Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Promega Corporation. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Transcriptomics Sale, by Type, Application, Product & Services, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Transcriptomics (Value)
      • 7.2.1. Global Transcriptomics by: Type (Value)
        • 7.2.1.1. Microarray
        • 7.2.1.2. Real-time PCR
        • 7.2.1.3. Sequencing Technology [Sanger Sequencing, RNA-Sequencing]
      • 7.2.2. Global Transcriptomics by: Application (Value)
        • 7.2.2.1. Diagnostics & Disease Profiling
        • 7.2.2.2. Drug Discovery
        • 7.2.2.3. Others
      • 7.2.3. Global Transcriptomics by: Product & Services (Value)
        • 7.2.3.1. Consumables
        • 7.2.3.2. Instruments
        • 7.2.3.3. Software
        • 7.2.3.4. Services
      • 7.2.4. Global Transcriptomics by: End User (Value)
        • 7.2.4.1. Government Institutes & Academic Centers
        • 7.2.4.2. Pharmaceutical & Biotechnology Companies
        • 7.2.4.3. Contract research Organizations (CROs)
      • 7.2.5. Global Transcriptomics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Transcriptomics (Price)
      • 7.3.1. Global Transcriptomics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transcriptomics: by Type(USD Million)
  • Table 2. Transcriptomics Microarray , by Region USD Million (2015-2020)
  • Table 3. Transcriptomics Real-time PCR , by Region USD Million (2015-2020)
  • Table 4. Transcriptomics Sequencing Technology [Sanger Sequencing, RNA-Sequencing] , by Region USD Million (2015-2020)
  • Table 5. Transcriptomics: by Application(USD Million)
  • Table 6. Transcriptomics Diagnostics & Disease Profiling , by Region USD Million (2015-2020)
  • Table 7. Transcriptomics Drug Discovery , by Region USD Million (2015-2020)
  • Table 8. Transcriptomics Others , by Region USD Million (2015-2020)
  • Table 9. Transcriptomics: by Product & Services(USD Million)
  • Table 10. Transcriptomics Consumables , by Region USD Million (2015-2020)
  • Table 11. Transcriptomics Instruments , by Region USD Million (2015-2020)
  • Table 12. Transcriptomics Software , by Region USD Million (2015-2020)
  • Table 13. Transcriptomics Services , by Region USD Million (2015-2020)
  • Table 14. Transcriptomics: by End User(USD Million)
  • Table 15. Transcriptomics Government Institutes & Academic Centers , by Region USD Million (2015-2020)
  • Table 16. Transcriptomics Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 17. Transcriptomics Contract research Organizations (CROs) , by Region USD Million (2015-2020)
  • Table 18. South America Transcriptomics, by Country USD Million (2015-2020)
  • Table 19. South America Transcriptomics, by Type USD Million (2015-2020)
  • Table 20. South America Transcriptomics, by Application USD Million (2015-2020)
  • Table 21. South America Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 22. South America Transcriptomics, by End User USD Million (2015-2020)
  • Table 23. Brazil Transcriptomics, by Type USD Million (2015-2020)
  • Table 24. Brazil Transcriptomics, by Application USD Million (2015-2020)
  • Table 25. Brazil Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 26. Brazil Transcriptomics, by End User USD Million (2015-2020)
  • Table 27. Argentina Transcriptomics, by Type USD Million (2015-2020)
  • Table 28. Argentina Transcriptomics, by Application USD Million (2015-2020)
  • Table 29. Argentina Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 30. Argentina Transcriptomics, by End User USD Million (2015-2020)
  • Table 31. Rest of South America Transcriptomics, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Transcriptomics, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 34. Rest of South America Transcriptomics, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Transcriptomics, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Transcriptomics, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Transcriptomics, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 39. Asia Pacific Transcriptomics, by End User USD Million (2015-2020)
  • Table 40. China Transcriptomics, by Type USD Million (2015-2020)
  • Table 41. China Transcriptomics, by Application USD Million (2015-2020)
  • Table 42. China Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 43. China Transcriptomics, by End User USD Million (2015-2020)
  • Table 44. Japan Transcriptomics, by Type USD Million (2015-2020)
  • Table 45. Japan Transcriptomics, by Application USD Million (2015-2020)
  • Table 46. Japan Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 47. Japan Transcriptomics, by End User USD Million (2015-2020)
  • Table 48. India Transcriptomics, by Type USD Million (2015-2020)
  • Table 49. India Transcriptomics, by Application USD Million (2015-2020)
  • Table 50. India Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 51. India Transcriptomics, by End User USD Million (2015-2020)
  • Table 52. South Korea Transcriptomics, by Type USD Million (2015-2020)
  • Table 53. South Korea Transcriptomics, by Application USD Million (2015-2020)
  • Table 54. South Korea Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 55. South Korea Transcriptomics, by End User USD Million (2015-2020)
  • Table 56. Taiwan Transcriptomics, by Type USD Million (2015-2020)
  • Table 57. Taiwan Transcriptomics, by Application USD Million (2015-2020)
  • Table 58. Taiwan Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 59. Taiwan Transcriptomics, by End User USD Million (2015-2020)
  • Table 60. Australia Transcriptomics, by Type USD Million (2015-2020)
  • Table 61. Australia Transcriptomics, by Application USD Million (2015-2020)
  • Table 62. Australia Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 63. Australia Transcriptomics, by End User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Transcriptomics, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Transcriptomics, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Transcriptomics, by End User USD Million (2015-2020)
  • Table 68. Europe Transcriptomics, by Country USD Million (2015-2020)
  • Table 69. Europe Transcriptomics, by Type USD Million (2015-2020)
  • Table 70. Europe Transcriptomics, by Application USD Million (2015-2020)
  • Table 71. Europe Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 72. Europe Transcriptomics, by End User USD Million (2015-2020)
  • Table 73. Germany Transcriptomics, by Type USD Million (2015-2020)
  • Table 74. Germany Transcriptomics, by Application USD Million (2015-2020)
  • Table 75. Germany Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 76. Germany Transcriptomics, by End User USD Million (2015-2020)
  • Table 77. France Transcriptomics, by Type USD Million (2015-2020)
  • Table 78. France Transcriptomics, by Application USD Million (2015-2020)
  • Table 79. France Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 80. France Transcriptomics, by End User USD Million (2015-2020)
  • Table 81. Italy Transcriptomics, by Type USD Million (2015-2020)
  • Table 82. Italy Transcriptomics, by Application USD Million (2015-2020)
  • Table 83. Italy Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 84. Italy Transcriptomics, by End User USD Million (2015-2020)
  • Table 85. United Kingdom Transcriptomics, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Transcriptomics, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 88. United Kingdom Transcriptomics, by End User USD Million (2015-2020)
  • Table 89. Netherlands Transcriptomics, by Type USD Million (2015-2020)
  • Table 90. Netherlands Transcriptomics, by Application USD Million (2015-2020)
  • Table 91. Netherlands Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 92. Netherlands Transcriptomics, by End User USD Million (2015-2020)
  • Table 93. Rest of Europe Transcriptomics, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Transcriptomics, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 96. Rest of Europe Transcriptomics, by End User USD Million (2015-2020)
  • Table 97. MEA Transcriptomics, by Country USD Million (2015-2020)
  • Table 98. MEA Transcriptomics, by Type USD Million (2015-2020)
  • Table 99. MEA Transcriptomics, by Application USD Million (2015-2020)
  • Table 100. MEA Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 101. MEA Transcriptomics, by End User USD Million (2015-2020)
  • Table 102. Middle East Transcriptomics, by Type USD Million (2015-2020)
  • Table 103. Middle East Transcriptomics, by Application USD Million (2015-2020)
  • Table 104. Middle East Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 105. Middle East Transcriptomics, by End User USD Million (2015-2020)
  • Table 106. Africa Transcriptomics, by Type USD Million (2015-2020)
  • Table 107. Africa Transcriptomics, by Application USD Million (2015-2020)
  • Table 108. Africa Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 109. Africa Transcriptomics, by End User USD Million (2015-2020)
  • Table 110. North America Transcriptomics, by Country USD Million (2015-2020)
  • Table 111. North America Transcriptomics, by Type USD Million (2015-2020)
  • Table 112. North America Transcriptomics, by Application USD Million (2015-2020)
  • Table 113. North America Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 114. North America Transcriptomics, by End User USD Million (2015-2020)
  • Table 115. United States Transcriptomics, by Type USD Million (2015-2020)
  • Table 116. United States Transcriptomics, by Application USD Million (2015-2020)
  • Table 117. United States Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 118. United States Transcriptomics, by End User USD Million (2015-2020)
  • Table 119. Canada Transcriptomics, by Type USD Million (2015-2020)
  • Table 120. Canada Transcriptomics, by Application USD Million (2015-2020)
  • Table 121. Canada Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 122. Canada Transcriptomics, by End User USD Million (2015-2020)
  • Table 123. Mexico Transcriptomics, by Type USD Million (2015-2020)
  • Table 124. Mexico Transcriptomics, by Application USD Million (2015-2020)
  • Table 125. Mexico Transcriptomics, by Product & Services USD Million (2015-2020)
  • Table 126. Mexico Transcriptomics, by End User USD Million (2015-2020)
  • Table 127. Transcriptomics: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Transcriptomics: by Type(USD Million)
  • Table 139. Transcriptomics Microarray , by Region USD Million (2021-2026)
  • Table 140. Transcriptomics Real-time PCR , by Region USD Million (2021-2026)
  • Table 141. Transcriptomics Sequencing Technology [Sanger Sequencing, RNA-Sequencing] , by Region USD Million (2021-2026)
  • Table 142. Transcriptomics: by Application(USD Million)
  • Table 143. Transcriptomics Diagnostics & Disease Profiling , by Region USD Million (2021-2026)
  • Table 144. Transcriptomics Drug Discovery , by Region USD Million (2021-2026)
  • Table 145. Transcriptomics Others , by Region USD Million (2021-2026)
  • Table 146. Transcriptomics: by Product & Services(USD Million)
  • Table 147. Transcriptomics Consumables , by Region USD Million (2021-2026)
  • Table 148. Transcriptomics Instruments , by Region USD Million (2021-2026)
  • Table 149. Transcriptomics Software , by Region USD Million (2021-2026)
  • Table 150. Transcriptomics Services , by Region USD Million (2021-2026)
  • Table 151. Transcriptomics: by End User(USD Million)
  • Table 152. Transcriptomics Government Institutes & Academic Centers , by Region USD Million (2021-2026)
  • Table 153. Transcriptomics Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 154. Transcriptomics Contract research Organizations (CROs) , by Region USD Million (2021-2026)
  • Table 155. South America Transcriptomics, by Country USD Million (2021-2026)
  • Table 156. South America Transcriptomics, by Type USD Million (2021-2026)
  • Table 157. South America Transcriptomics, by Application USD Million (2021-2026)
  • Table 158. South America Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 159. South America Transcriptomics, by End User USD Million (2021-2026)
  • Table 160. Brazil Transcriptomics, by Type USD Million (2021-2026)
  • Table 161. Brazil Transcriptomics, by Application USD Million (2021-2026)
  • Table 162. Brazil Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 163. Brazil Transcriptomics, by End User USD Million (2021-2026)
  • Table 164. Argentina Transcriptomics, by Type USD Million (2021-2026)
  • Table 165. Argentina Transcriptomics, by Application USD Million (2021-2026)
  • Table 166. Argentina Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 167. Argentina Transcriptomics, by End User USD Million (2021-2026)
  • Table 168. Rest of South America Transcriptomics, by Type USD Million (2021-2026)
  • Table 169. Rest of South America Transcriptomics, by Application USD Million (2021-2026)
  • Table 170. Rest of South America Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 171. Rest of South America Transcriptomics, by End User USD Million (2021-2026)
  • Table 172. Asia Pacific Transcriptomics, by Country USD Million (2021-2026)
  • Table 173. Asia Pacific Transcriptomics, by Type USD Million (2021-2026)
  • Table 174. Asia Pacific Transcriptomics, by Application USD Million (2021-2026)
  • Table 175. Asia Pacific Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 176. Asia Pacific Transcriptomics, by End User USD Million (2021-2026)
  • Table 177. China Transcriptomics, by Type USD Million (2021-2026)
  • Table 178. China Transcriptomics, by Application USD Million (2021-2026)
  • Table 179. China Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 180. China Transcriptomics, by End User USD Million (2021-2026)
  • Table 181. Japan Transcriptomics, by Type USD Million (2021-2026)
  • Table 182. Japan Transcriptomics, by Application USD Million (2021-2026)
  • Table 183. Japan Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 184. Japan Transcriptomics, by End User USD Million (2021-2026)
  • Table 185. India Transcriptomics, by Type USD Million (2021-2026)
  • Table 186. India Transcriptomics, by Application USD Million (2021-2026)
  • Table 187. India Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 188. India Transcriptomics, by End User USD Million (2021-2026)
  • Table 189. South Korea Transcriptomics, by Type USD Million (2021-2026)
  • Table 190. South Korea Transcriptomics, by Application USD Million (2021-2026)
  • Table 191. South Korea Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 192. South Korea Transcriptomics, by End User USD Million (2021-2026)
  • Table 193. Taiwan Transcriptomics, by Type USD Million (2021-2026)
  • Table 194. Taiwan Transcriptomics, by Application USD Million (2021-2026)
  • Table 195. Taiwan Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 196. Taiwan Transcriptomics, by End User USD Million (2021-2026)
  • Table 197. Australia Transcriptomics, by Type USD Million (2021-2026)
  • Table 198. Australia Transcriptomics, by Application USD Million (2021-2026)
  • Table 199. Australia Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 200. Australia Transcriptomics, by End User USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Transcriptomics, by Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Transcriptomics, by Application USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Transcriptomics, by End User USD Million (2021-2026)
  • Table 205. Europe Transcriptomics, by Country USD Million (2021-2026)
  • Table 206. Europe Transcriptomics, by Type USD Million (2021-2026)
  • Table 207. Europe Transcriptomics, by Application USD Million (2021-2026)
  • Table 208. Europe Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 209. Europe Transcriptomics, by End User USD Million (2021-2026)
  • Table 210. Germany Transcriptomics, by Type USD Million (2021-2026)
  • Table 211. Germany Transcriptomics, by Application USD Million (2021-2026)
  • Table 212. Germany Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 213. Germany Transcriptomics, by End User USD Million (2021-2026)
  • Table 214. France Transcriptomics, by Type USD Million (2021-2026)
  • Table 215. France Transcriptomics, by Application USD Million (2021-2026)
  • Table 216. France Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 217. France Transcriptomics, by End User USD Million (2021-2026)
  • Table 218. Italy Transcriptomics, by Type USD Million (2021-2026)
  • Table 219. Italy Transcriptomics, by Application USD Million (2021-2026)
  • Table 220. Italy Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 221. Italy Transcriptomics, by End User USD Million (2021-2026)
  • Table 222. United Kingdom Transcriptomics, by Type USD Million (2021-2026)
  • Table 223. United Kingdom Transcriptomics, by Application USD Million (2021-2026)
  • Table 224. United Kingdom Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 225. United Kingdom Transcriptomics, by End User USD Million (2021-2026)
  • Table 226. Netherlands Transcriptomics, by Type USD Million (2021-2026)
  • Table 227. Netherlands Transcriptomics, by Application USD Million (2021-2026)
  • Table 228. Netherlands Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 229. Netherlands Transcriptomics, by End User USD Million (2021-2026)
  • Table 230. Rest of Europe Transcriptomics, by Type USD Million (2021-2026)
  • Table 231. Rest of Europe Transcriptomics, by Application USD Million (2021-2026)
  • Table 232. Rest of Europe Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 233. Rest of Europe Transcriptomics, by End User USD Million (2021-2026)
  • Table 234. MEA Transcriptomics, by Country USD Million (2021-2026)
  • Table 235. MEA Transcriptomics, by Type USD Million (2021-2026)
  • Table 236. MEA Transcriptomics, by Application USD Million (2021-2026)
  • Table 237. MEA Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 238. MEA Transcriptomics, by End User USD Million (2021-2026)
  • Table 239. Middle East Transcriptomics, by Type USD Million (2021-2026)
  • Table 240. Middle East Transcriptomics, by Application USD Million (2021-2026)
  • Table 241. Middle East Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 242. Middle East Transcriptomics, by End User USD Million (2021-2026)
  • Table 243. Africa Transcriptomics, by Type USD Million (2021-2026)
  • Table 244. Africa Transcriptomics, by Application USD Million (2021-2026)
  • Table 245. Africa Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 246. Africa Transcriptomics, by End User USD Million (2021-2026)
  • Table 247. North America Transcriptomics, by Country USD Million (2021-2026)
  • Table 248. North America Transcriptomics, by Type USD Million (2021-2026)
  • Table 249. North America Transcriptomics, by Application USD Million (2021-2026)
  • Table 250. North America Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 251. North America Transcriptomics, by End User USD Million (2021-2026)
  • Table 252. United States Transcriptomics, by Type USD Million (2021-2026)
  • Table 253. United States Transcriptomics, by Application USD Million (2021-2026)
  • Table 254. United States Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 255. United States Transcriptomics, by End User USD Million (2021-2026)
  • Table 256. Canada Transcriptomics, by Type USD Million (2021-2026)
  • Table 257. Canada Transcriptomics, by Application USD Million (2021-2026)
  • Table 258. Canada Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 259. Canada Transcriptomics, by End User USD Million (2021-2026)
  • Table 260. Mexico Transcriptomics, by Type USD Million (2021-2026)
  • Table 261. Mexico Transcriptomics, by Application USD Million (2021-2026)
  • Table 262. Mexico Transcriptomics, by Product & Services USD Million (2021-2026)
  • Table 263. Mexico Transcriptomics, by End User USD Million (2021-2026)
  • Table 264. Transcriptomics: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transcriptomics: by Type USD Million (2015-2020)
  • Figure 5. Global Transcriptomics: by Application USD Million (2015-2020)
  • Figure 6. Global Transcriptomics: by Product & Services USD Million (2015-2020)
  • Figure 7. Global Transcriptomics: by End User USD Million (2015-2020)
  • Figure 8. South America Transcriptomics Share (%), by Country
  • Figure 9. Asia Pacific Transcriptomics Share (%), by Country
  • Figure 10. Europe Transcriptomics Share (%), by Country
  • Figure 11. MEA Transcriptomics Share (%), by Country
  • Figure 12. North America Transcriptomics Share (%), by Country
  • Figure 13. Global Transcriptomics: by Type USD/Units (2015-2020)
  • Figure 14. Global Transcriptomics share by Players 2020 (%)
  • Figure 15. Global Transcriptomics share by Players (Top 3) 2020(%)
  • Figure 16. Global Transcriptomics share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. QIAGEN (Exiqon) (Germany) Revenue, Net Income and Gross profit
  • Figure 19. QIAGEN (Exiqon) (Germany) Revenue: by Geography 2020
  • Figure 20. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Illumina, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 25. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 26. GE Healthcare Dharmacon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. GE Healthcare Dharmacon Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 32. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Fluidigm Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Fluidigm Corporation (United States) Revenue: by Geography 2020
  • Figure 36. Promega Corporation. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Promega Corporation. (United States) Revenue: by Geography 2020
  • Figure 38. Global Transcriptomics: by Type USD Million (2021-2026)
  • Figure 39. Global Transcriptomics: by Application USD Million (2021-2026)
  • Figure 40. Global Transcriptomics: by Product & Services USD Million (2021-2026)
  • Figure 41. Global Transcriptomics: by End User USD Million (2021-2026)
  • Figure 42. South America Transcriptomics Share (%), by Country
  • Figure 43. Asia Pacific Transcriptomics Share (%), by Country
  • Figure 44. Europe Transcriptomics Share (%), by Country
  • Figure 45. MEA Transcriptomics Share (%), by Country
  • Figure 46. North America Transcriptomics Share (%), by Country
  • Figure 47. Global Transcriptomics: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • QIAGEN (Exiqon) (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Illumina, Inc. (United States)
  • Agilent Technologies (United States)
  • GE Healthcare Dharmacon Inc. (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Merck & Co., Inc. (United States)
  • Fluidigm Corporation (United States)
  • Promega Corporation. (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 216 Pages 55 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Transcriptomics market is expected to see a CAGR of 13.2% during projected year 2020 to 2026.
Top performing companies in the Global Transcriptomics market are QIAGEN (Exiqon) (Germany), Thermo Fisher Scientific Inc. (United States), Illumina, Inc. (United States), Agilent Technologies (United States), GE Healthcare Dharmacon Inc. (United States), Bio-Rad Laboratories, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (United States), Fluidigm Corporation (United States) and Promega Corporation. (United States), to name a few.
North America is dominating the Transcriptomics Market.

Know More About Global Transcriptomics Market Report?